

Prescribing Clinical Network

Policy Statement	Febuxostat for the management of chronic hyperuricaemia in gout (NICE TA 164)
Policy No:	PCN 361 - 2018 (replaces PCN 58-2013)
Date of Issue	September 2018
Review Date:	September 2021 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
Recommendations: <p>The Prescribing Clinical Network recommends the use of febuxostat in line with NICE TA 164, for the management of chronic hyperuricaemia in gout only for people who are intolerant of allopurinol (as defined in TA) or for whom allopurinol is contraindicated.</p> <p>Febuxostat is considered to have a GREEN status on the traffic light system.</p>	
Key Considerations: <ul style="list-style-type: none"> For the purposes of this guidance, intolerance of allopurinol is defined as adverse effects that are sufficiently severe to warrant its discontinuation, or to prevent full dose escalation for optimal effectiveness as appropriate within its marketing authorisation. This is a review of the PCN recommendation made in May 2013 	
Date taken to Prescribing Clinical Network	5 th September 2018
Agreed by PCN members	18th September 2018

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG